Try our Advanced Search for more refined results
Fresenius Kabi USA, LLC Inter Partes Review
Case Number:
Case Type:
IPR
Status:
Terminated-Settled
Petitioner:
Fresenius Kabi USA, LLC
Patent Owner:
Tech Center:
-
Filed: June 28, 2021 00:00
Coverage
-
January 07, 2022
'Hypothetical' Suit Won't Shield Roche Patents From Review
The Patent Trial and Appeal Board on Thursday instituted inter partes reviews of two patents on Roche unit Chugai's arthritis and COVID-19 monoclonal antibody drug Actemra, ruling that "hypothetical future district court litigation" over a biosimilar planned by Fresenius is no reason not to review the patents.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Search PTAB cases and full-text documents.
- Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
- Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
View the PTAB case documentsAlready a subscriber? Click here to login
-
January 07, 2022